Prochymal^® Expanded access program For Pediatric patients with Steroid-Refractory Acute GvHD

Accepting patients

This program allows for the treatment of pediatric patients with steroid-refractory acute GvHD. Clearance for this program was granted by the U.S. Food and Drug Administration to make Prochymal available to children with life-threatening GvHD.

Program Overview

Click Here for more information

If you have questions about this clinical program, please email us at GvHD@Osiris.com